Author: Ken Dropiewski

Neovasc’s Management and Board of Directors Urge Shareholders to Vote In Favor of the Proposed Reverse Stock Split at the Upcoming Annual General and Special Meeting of Shareholders

VANCOUVER, May 15, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its management and board of directors (the “Board”) urge the Company’s shareholders of record to vote “FOR” the proposal authorizing the […]

BrainQ Technologies Raises $8.8 Million to Treat Neurodisorders With Artificial Intelligence

JERUSALEM, May 15, 2018 /PRNewswire/ — BrainQ, developing Artificial Intelligence (AI) powered technologies to treat neurodisorders in innovative ways, today announced the completion of a financing round, making the total investment in the Company to date stand at $8.8M. The financing included Qure Ventures, OurCrowd.com, Norma Investments, IT-Farm, and other strategic angel investors […]

New Analysis Shows Medtronic Cardiac Resynchronization Therapy Feature Associated with Improved Patient Survival

DUBLIN – May 15, 2018 – Medtronic plc (NYSE: MDT) announced study results showing its exclusive AdaptivCRT(TM) algorithm is associated with improved patient survival. The data were recently presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions in Boston. In a real-world, prospective registry of 1,835 patients, use […]

Ancora Heart Expands Enrollment of U.S. Early Feasibility Study for the AccuCinch System for Left Ventricular Repair

SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced the expansion of the company’s U.S. feasibility study to evaluate the investigational AccuCinch®Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation (FMR). Ancora has received approval from […]

Boston Scientific To Participate In 34th Annual Strategic decisions Conference

MARLBOROUGH, Mass., May 14, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 34th Annual Strategic Decisions Conference on May 31, 2018 in New York. Mike Mahoney, chairman and chief executive officer, will participate in a 50-minute presentation and question-and-answer session with the host analyst beginning at approximately 8:00 a.m. EDT. A live […]

Zynex Announces Share Buyback Program

ENGLEWOOD, Colo., May 14, 2018 /PRNewswire/ — Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that its board of directors approved a program to buy back an additional $2 million of […]

Edwards Lifesciences To Webcast Annual Meeting Of Stockholders

IRVINE, Calif., May 14, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will host its Annual Meeting of Stockholders on Thursday, May 17, 2018 beginning at 10:00 a.m. PT (1:00 pm ET) at its corporate headquarters in Irvine, California. A live webcast of the […]

Surmodics Acquires Thrombectomy Technology Assets from Embolitech, Strengthening Peripheral Vascular Whole-Product Solutions Portfolio

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today it has reached an agreement with Embolitech to acquire an innovative thrombectomy platform technology and related intellectual property with broad potential peripheral vascular applications. Under the […]

Parker Waichman LLP is Investigating Potential Neurovascular Stent Claims Following Recent FDA Safety Alert

NEW YORK, May 14, 2018 /PRNewswire/ — Parker Waichman LLP is investigating potential personal injury and defective medical device claims related to adverse events associated with the use of Neurovascular Stents for Stent-Assisted Coiling (SAC) for the treatment of unruptured brain aneurysms. The Food and Drug Administration (FDA) has received […]